NCT04270604TERMINATEDanonymous

Biological Sample Collection for Research and Biobanking

Sponsor

Source record

New York Stem Cell Foundation Research Institute

Phase

Source record

Not applicable; this is an observational study and not classified under traditional clinical trial phases.

Modality

AI-normalized

protein therapy

Target

AI-normalized

Not applicable; the study focuses on biological sample collection rather than a specific molecular or mechanistic target.

Indication / condition

AI-normalized

Parkinson Disease

Intervention

Source record

Biological sample collection

Source & freshness

Source record

NCT ID

NCT04270604

Original source

ClinicalTrials.gov

Source last updated

Aug 02, 2024

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04270604

Title

Biological Sample Collection for Research and Biobanking

Sponsor

New York Stem Cell Foundation Research Institute

Status

TERMINATED

Phase

Not applicable; this is an observational study and not classified under traditional clinical trial phases.

Condition raw

Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease

Condition normalized

Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

Not applicable; the study focuses on biological sample collection rather than a specific molecular or mechanistic target.

Target normalized

Not applicable; the study focuses on biological sample collection rather than a specific molecular or mechanistic target.

Interventions

Biological sample collection

Public preview

Source record

The New York Stem Cell Foundation Research Institute's biobanking initiative aims to collect and store biological samples for future research on various diseases, including Parkinson's disease, Type 1 diabetes, and Alzheimer's disease. This initiative positions NYSCF as a key player in the regenerative medicine and genetic research sectors, potentially leading to the development of novel therapies. The termination of this study to focus on an alternative biobanking protocol suggests a strategic pivot that may enhance operational efficiency or align better with emerging research priorities. Stakeholders should monitor NYSCF's future initiatives for potential collaborations or investment opportunities, particularly in the context of advancing personalized medicine and genetic therapies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Biological Sample Collection for Research and Biobanking

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT04270604

Status

TERMINATED

Phase

Not applicable; this is an observational study and not classified under traditional clinical trial phases.

Sponsor

New York Stem Cell Foundation Research Institute

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 02, 2024

Internal syncJun 16, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04270604

Indication

Parkinson Disease

Modality

protein therapy

Target

Not applicable; the study focuses on biological sample collection rather than a specific molecular or mechanistic target.

Intervention

Biological sample collection

Source record